Device Trial Radar · NCT04835844
RHYTHMIA vs CARTO in Redo Ablation Procedures for Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jul 24, 2020
Primary completion
Jul 11, 2025
Study completion Jul 11, 2025
Sponsor
- Lead sponsor
- The Cleveland ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation
- First posted
- Apr 8, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The MAP-AF study will compare RHYTHMIA vs CARTO in redo ablation of paroxysmal AF with assessment of both acute procedural profiles and clinical outcomes.
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
CARTODevice
Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
RHYTHMIADevice
Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- System is able to accurately identify gapsTime frame: At the time of procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.